Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.

Angelo Borsarelli Carvalho BritoMarcos Pedro Guedes CamandarobaVladmir Cláudio Cordeiro de Lima

Published in: Thoracic cancer (2021)

Our study suggests that PD-1 drug plus chemotherapy is superior to anti-PD-L1 plus chemotherapy for NSCLC; nevertheless, as monotherapy, both strategies appear to be similar.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
locally advanced
small cell lung cancer
emergency department
open label
radiation therapy
chemotherapy induced
adverse drug